AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 25

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UHP3

UPID:

UBP25_HUMAN

Alternative names:

Deubiquitinating enzyme 25; USP on chromosome 21; Ubiquitin thioesterase 25; Ubiquitin-specific-processing protease 25

Alternative UPACC:

Q9UHP3; C0LSZ0; Q6DHZ9; Q9H9W1

Background:

Ubiquitin carboxyl-terminal hydrolase 25 (USP25) emerges as a critical deubiquitinating enzyme, pivotal in ubiquitin-dependent signaling pathways. It uniquely processes and recycles ubiquitin molecules, editing polyubiquitin chains to avert proteasomal degradation of substrates. Notably, USP25 exhibits versatility by hydrolyzing both 'Lys-48'- and 'Lys-63'-linked tetraubiquitin chains. The muscle-specific isoform, USP25m, is implicated in muscular differentiation and function, highlighting its specialized roles.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 25 could open doors to potential therapeutic strategies. Its involvement in ubiquitin signaling pathways underscores its potential as a target for modulating protein degradation processes, crucial in various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.